Prevalence and Risk Factors for Venous Thromboembolic Events in Critically Ill Patients With SARS-CoV-2 Infection
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- SARS Virus
- Sponsor
- Chiesa Alessandro Felice
- Enrollment
- 80
- Locations
- 1
- Primary Endpoint
- Period prevalence of deep vein thrombosis (DVT)
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
The purpose of the study is to assess the frequency of the occurrence of a venous thrombosis in patients with the new Coronavirus disease, who are admitted to the Intensive Care Unit for impending respiratory failure requiring intubation and mechanical ventilation. Furthermore, the investigators aim at identifying potential risk factors for thrombosis and death.
Detailed Description
Symptomatic infection with the severe acute respiratory syndrome coronavirus 2 ranges from mild to critical spectrum. About 80% of laboratory confirmed infections presented with mild symptoms, usually not requiring hospitalization. Critical disease requiring respiratory and/or circulatory support was reported in 5% of the subjects. Acute respiratory distress syndrome represents the most common complication in patients with severe disease. Several cases of venous thromboembolism in patients with laboratory confirmed infection have been reported, but it is unclear if this occurrence is higher in this specific patients' population. The purpose of the present study is to assess the prevalence of deep venous thrombosis in patients infected with SARS-CoV-2 admitted to the Intensive care Unit requiring invasive mechanical ventilation using vein ultrasonography.
Investigators
Chiesa Alessandro Felice
Principal Investigator
Ente Ospedaliero Cantonale, Bellinzona
Eligibility Criteria
Inclusion Criteria
- •patients admitted to the Intensive Care Unit
- •laboratory confirmed SARS-CoV-2 infection
- •invasive respiratory support
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Period prevalence of deep vein thrombosis (DVT)
Time Frame: From date of inclusion in the study until the date of development of a DVT, date of death from any cause, or date of discharge from the ICU, whichever came first, assessed up to 3 months
Percent (%) of patients with a DVT